-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec content team editor
Short bowel syndrome (SBS) is a rare, debilitating condition
caused by the loss of a functional small intestine.
In adults, short bowel syndrome is usually caused
by trauma, vascular disease, malignancy, and resection of the bowel due to chronic enteritis (IBD).
Residual short intestinal intestines are often shorter than 200 cm, resulting in loss
of surface area for nutrient, fluid and drug absorption.
Short bowel syndrome can lead to intestinal failure (IF), which is a decrease in bowel function to the minimum required for the body's absorption of
nutrients, water, and electrolytes.
Due to complications such as diarrhoea, dehydration and malnutrition, the quality of life and life expectancy of people with short bowel syndrome are severely affected
.
There are an estimated 15,000 to 20,000 people with short bowel syndrome in
the United States.
Patients with continuous colon account for about 55% of patients with SBS-IF, and the colon of these patients is connected to
the remaining small intestine.
The presence of a functional colon allows these patients to absorb adequate water orally, and intravenous infusion support is primarily intended to obtain adequate nutrition and energy
.
Image source: 123RF
.
If you have related business needs, please click the picture below to fill in the specific information
.
▲If you have any business needs, please long press to scan the QR code above, or
VectivBio today announced the positive results
of its interim analysis of its GLP-2 agonist apraglutide in a Phase 2 clinical trial.
Data analysis showed that about eighty percent of patients with short bowel syndrome (SBS-IF) with bowel failure achieved remission and did not require intravenous support
for at least 1 day of 6 months of treatment.
This trial is the first clinical program
to examine and demonstrate the efficacy of GLP-2 agonists in patients with continuous colonic (CIC) SBS-IF.
Short bowel syndrome (SBS) is a rare, debilitating condition
caused by the loss of a functional small intestine.
In adults, short bowel syndrome is usually caused
by trauma, vascular disease, malignancy, and resection of the bowel due to chronic enteritis (IBD).
Residual short intestinal intestines are often shorter than 200 cm, resulting in loss
of surface area for nutrient, fluid and drug absorption.
Short bowel syndrome can lead to intestinal failure (IF), which is a decrease in bowel function to the minimum required for the body's absorption of
nutrients, water, and electrolytes.
Due to complications such as diarrhoea, dehydration and malnutrition, the quality of life and life expectancy of people with short bowel syndrome are severely affected
.
There are an estimated 15,000 to 20,000 people with short bowel syndrome in
the United States.
Patients with continuous colon account for about 55% of patients with SBS-IF, and the colon of these patients is connected to
the remaining small intestine.
The presence of a functional colon allows these patients to absorb adequate water orally, and intravenous infusion support is primarily intended to obtain adequate nutrition and energy
.
Apraglutide is an investigational, next-generation, long-acting GLP-2 synthetic analog developed for the treatment of a range of rare gastrointestinal disorders, including SBS-IF and acute graft-versus-host disease (aGVHD).
Image source: 123RF
STARS Nutrition is a multicenter, open-label, Phase 2 clinical trial to examine the effect
of once-weekly apraglutide on enteric absorption and the need for intravenous infusion in patients with SBS-IF with continuous colon.
The trial involved nine adults with an average age of 46.
8 years
.
By the data deadline of October 7, 2022, 5 of the 9 patients had completed at least 6 months of treatment
.
Interim analysis showed an average of 50% reduction in the volume of intravenous support required and a 47% decrease
in intravenous infusion energy content among patients who received weekly apraglutide for 6 months.
Eighty percent of these patients (n=4/5) achieved clinical remission (i.
e.
, at least a 20% reduction in the volume required for intravenous support) and did not require intravenous support
for at least 1 day of 6 months.
Among the nine patients who had been treated for at least 3 months, the average intravenous infusion was reduced by 31%
after the third month of treatment.
"We are pleased with this interim clinical data, which shows that apraglutide has the potential to help patients with SBS-IF with continuous colon who are in dire need of new, effective drugs," said Dr.
Omar Khwaja, Chief Marketing Officer of VectivBio.
best-in-class's GLP-2 analogue, a therapeutic area with a high medical unmet need
.
We look forward to sharing 6 months of top-line data on treatment for all 9 of our patients in the coming months
.
" ”
.
If you have related business needs, please click the picture below to fill in the specific information
.
▲If you have any business needs, please long press to scan the QR code above, or
